Breast, Pfizer-C4891001

VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease

Breast, NRG-BR007

DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18

Breast, CELC-G-301

Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer

Breast, Ascent 03

Trodelvy vs MD Choice for Untreated PD-L1 Negative mTNBC or PD-L1 Positive Previously Treated w/ Anti PD-L1 Therapy Who Recur

Breast, A011801

CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

February's "Cancer News from HOA" on 93Q with Amy Robbins: Dr. Gajra discusses the latest in immunotherapy

Dr. Gajra talks about the latest in Immunotherapy when it comes to cancer treatment in February’s interview below.

Patient Newsletter 2023 February

Patient Newsletter 2023 January

Young Women with Breast Cancer Support Group For women in their 20s, 30s, 40s

5-6pm on Wednesdays January 11 - February 15, 2023.   

At Hematology Oncology Associates of CNY
5008 Brittonfield Parkway
East Syracuse, NY 13057

Please register by emailing or calling Pamela Coffey, 472-7504 ext 1608 or pcoffey@hoacny.com

Pages